Search tips
Search criteria

Results 1-8 (8)

Clipboard (0)
Year of Publication
1.  Platelet storage lesion: An update 
PMCID: PMC4339916  PMID: 25722562
4.  Hemovigilance and blood safety 
PMCID: PMC3439750  PMID: 22988376
5.  Automation in Immunohematology 
There have been rapid technological advances in blood banking in South Asian region over the past decade with an increasing emphasis on quality and safety of blood products. The conventional test tube technique has given way to newer techniques such as column agglutination technique, solid phase red cell adherence assay, and erythrocyte-magnetized technique. These new technologies are adaptable to automation and major manufacturers in this field have come up with semi and fully automated equipments for immunohematology tests in the blood bank. Automation improves the objectivity and reproducibility of tests. It reduces human errors in patient identification and transcription errors. Documentation and traceability of tests, reagents and processes and archiving of results is another major advantage of automation. Shifting from manual methods to automation is a major undertaking for any transfusion service to provide quality patient care with lesser turnaround time for their ever increasing workload. This article discusses the various issues involved in the process.
PMCID: PMC3439752  PMID: 22988378
Automation; immunohematology; serology
6.  Rare blood donor program in the country: Right time to start 
PMCID: PMC3353620  PMID: 22623833
8.  Hemolytic disease of the fetus and newborn: Current trends and perspectives 
The spectrum of hemolytic disease of the newborn has changed over the last few decades. With the implementation of Rhesus D immunoprophylaxis, hemolytic disease due to ABO incompatibility and other alloantibodies has now emerged as major causes of this condition. Though in developing countries, anti D is still a common antibody in pregnant women, many Asian countries have identified alloantibodies other than anti D as a cause of moderate-severe hemolytic disease. The most concerned fact is that, some of these have been described in Rh D positive women. It appears that universal antenatal screening in all pregnant women needs to be initiated, since Rh D positive women are just as likely as D negative women to form alloantibodies. Many developed nations have national screening programs for pregnant women. This is necessary to ensure timely availability of antigen negative blood and reduce effects on the newborn. Although universal screening seems justified, the cost and infrastructure required would be immense. Developing countries and under resourced nations need to consider universal antenatal screening and frame guidelines accordingly.
PMCID: PMC3082712  PMID: 21572705
Newborn hemolytic disease; red cell alloimmunisation; antenatal antibody screening

Results 1-8 (8)